ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on the characterization of WU-CART-007 at the 63rd Annual Meeting of the American Society of Hematology (ASH) which will be held virtually and in-person in Atlanta, Georgia from December 11-14, 2021. The results demonstrate preclinical safety and anti-tumor activity of WU-CART-007. Wugen is preparing to begin enrollment for a Phase 1/2 clinical trial for relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL) (NCT#04984356).
The details of Wugen’s presentation at ASH are as follows:
- Title: Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies
- Abstract Number: 2772
- Poster session: Session 703. Cellular Immunotherapies: Basic and Translational
- Date and time: Sunday, December 12, 2021, 6:00 – 8:00 p.m. ET
- Location: Hall B5 (Georgia World Congress Center)
- Authors: Tom Leedom, Alexander S. Hamil, Ph.D., Somayeh Pouyanfard, Jennifer Govero, Ph.D., Rachel Langland, B.Sc., Anna Ballard, Ph.D., Liz Schwarzkopf, Andrew Martens, Andrew Espenschied, Pooja Vinay, M.S., Michael James, Nitin Mahajan, Ph.D., David H. Spencer, M.D., Kenneth M. Chrobak, Ph.D., Matthew L Cooper, Ph.D., and Ayman Kabakibi, Ph.D.
About Wugen
Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in clinical development for acute myelogenous leukemia (AML). Wugen is also advancing WU-CART-007, currently in development for T-cell acute lymphoblastic leukemia (T-ALL). For more information, please visit www.wugen.com.
Contacts
Investor Contact:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com